Log in

Relevant bibliographies by topics / Antitumour / Journal articles

To see the other types of publications on this topic, follow the link: Antitumour.

Journal articles on the topic 'Antitumour'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antitumour.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sreco-Zelenovic, Bojana, Sanja Grabez, Mirjana Popsavin, Vesna Kojic, Jovana Francuz, and Velimir Popsavin. "Synthesis and antiproliferative activity of simplified goniofufurone analogues." Journal of the Serbian Chemical Society, no. 00 (2020): 56. http://dx.doi.org/10.2298/jsc200730056s.

Full text

Abstract:

Several (+)-goniofufurone analogues with simplified structures were designed, synthesized and evaluated for their in vitro antitumour activity against a panel of human tumour cell lines. Dephenylated compounds 2 and 3, demonstrated remarkable antitumour activities, in the cultures of K562 and Raji cells with IC50 values in the range of 3.0-9.3 nM. Each of goniofufurone analogues lacking the tetrahydrofuran ring (4, 5 and 6) strongly inhibited the growth of at least one malignant cell line, with IC50 values in the range of 11-30 nM. Brief SAR analysis showed that the simplified goniofufurone an

APA, Harvard, Vancouver, ISO, and other styles

2

Asche, C. "Antitumour Quinones." Mini-Reviews in Medicinal Chemistry 5, no. 5 (2005): 449–67. http://dx.doi.org/10.2174/1389557053765556.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Demeunynck, Martine. "Antitumour acridines." Expert Opinion on Therapeutic Patents 14, no. 1 (2004): 55–70. http://dx.doi.org/10.1517/13543776.14.1.55.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Slack, J. A., and C. Goddard. "Antitumour imidazotetrazines." Journal of Chromatography B: Biomedical Sciences and Applications 337 (January 1985): 178–81. http://dx.doi.org/10.1016/0378-4347(85)80027-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Jones, Bryony. "Evading antitumour immunity." Nature Reviews Cancer 16, no. 7 (2016): 410. http://dx.doi.org/10.1038/nrc.2016.65.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Jones, Bryony. "Evading antitumour immunity." Nature Reviews Genetics 17, no. 7 (2016): 374. http://dx.doi.org/10.1038/nrg.2016.77.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Mitra, Roshni, Sarvjeet Singh, and Ashok Khar. "Antitumour immune responses." Expert Reviews in Molecular Medicine 5, no. 3 (2003): 1–22. http://dx.doi.org/10.1017/s1462399403005623.

Full text

Abstract:

The role of the immune system in combating tumour progression has been studied extensively. The two branches of the immune response – humoral and cell-mediated – act both independently and in concert to combat tumour progression, the success of which depends on the immunogenicity of the tumour cells. The immune system discriminates between transformed cells and normal cells by virtue of the presence of unique antigens on tumour cells. Despite this, the immune system is not always able to detect and kill cancerous cells because neoplasms have also evolved various strategies to escape immune sur

APA, Harvard, Vancouver, ISO, and other styles

8

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 8, no. 1 (2003): 47–50. http://dx.doi.org/10.1016/s1359-6446(02)02551-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 8, no. 5 (2003): 229–31. http://dx.doi.org/10.1016/s1359-6446(03)02622-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Westwell, A. "Novel antitumour molecules." Drug Discovery Today 8, no. 9 (2003): 421–22. http://dx.doi.org/10.1016/s1359-6446(03)02676-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 8, no. 15 (2003): 718–19. http://dx.doi.org/10.1016/s1359-6446(03)02776-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 8, no. 20 (2003): 955–57. http://dx.doi.org/10.1016/s1359-6446(03)02834-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Westwell, Andrew. "Novel antitumour molecules." Drug Discovery Today 6, no. 4 (2001): 215–16. http://dx.doi.org/10.1016/s1359-6446(00)01619-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Westwell, Andrew. "Novel antitumour molecules." Drug Discovery Today 6, no. 9 (2001): 489–91. http://dx.doi.org/10.1016/s1359-6446(01)01755-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Westwell, Andrew. "Novel antitumour molecules." Drug Discovery Today 6, no. 12 (2001): 648–49. http://dx.doi.org/10.1016/s1359-6446(01)01829-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 6, no. 13 (2001): 699–701. http://dx.doi.org/10.1016/s1359-6446(01)01836-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Westwell, Andrew. "Novel antitumour molecules." Drug Discovery Today 6, no. 17 (2001): 916–18. http://dx.doi.org/10.1016/s1359-6446(01)01915-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 7, no. 4 (2002): 269–72. http://dx.doi.org/10.1016/s1359-6446(01)02141-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 7, no. 13 (2002): 739–40. http://dx.doi.org/10.1016/s1359-6446(02)02311-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 7, no. 14 (2002): 780–83. http://dx.doi.org/10.1016/s1359-6446(02)02331-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Tisdale, Michael J. "Antitumour imidazotetrazines—X." Biochemical Pharmacology 35, no. 2 (1986): 311–16. http://dx.doi.org/10.1016/0006-2952(86)90531-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Tisdale, Michael J. "Antitumour imidazotetrazines—XV." Biochemical Pharmacology 36, no. 4 (1987): 457–62. http://dx.doi.org/10.1016/0006-2952(87)90351-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Bull, Vincent L., and Michael J. Tisdale. "Antitumour imidazotetrazines—XVI." Biochemical Pharmacology 36, no. 19 (1987): 3215–20. http://dx.doi.org/10.1016/0006-2952(87)90636-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Tisdale, Michael J. "Antitumour imidazotetrazines—XVIII." Biochemical Pharmacology 38, no. 7 (1989): 1097–101. http://dx.doi.org/10.1016/0006-2952(89)90254-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Horgan, Carmel M. T., and Michael J. Tisdale. "Antitumour imidazotetrazines—VIII." Biochemical Pharmacology 34, no. 2 (1985): 217–21. http://dx.doi.org/10.1016/0006-2952(85)90127-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Minton, Kirsty. "Enhancing antitumour eosinophils." Nature Reviews Immunology 19, no. 4 (2019): 202–3. http://dx.doi.org/10.1038/s41577-019-0142-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hepburn, Paul A., and Michael J. Tisdale. "Antitumour imidazotetrazines—XXIV." Biochemical Pharmacology 41, no. 3 (1991): 339–43. http://dx.doi.org/10.1016/0006-2952(91)90529-e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Bouma, J., J. H. Beijnen, A. Bult, and W. J. M. Underberg. "Anthracycline antitumour agents." Pharmaceutisch Weekblad Scientific Edition 8, no. 2 (1986): 109–33. http://dx.doi.org/10.1007/bf02086146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Westwell, Andrew D. "Novel antitumour agents." Drug Discovery Today 11, no. 23-24 (2006): 1122–23. http://dx.doi.org/10.1016/j.drudis.2006.09.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Zhang, Ling, Jian-Hui Zhang, and Da-yuan Zhu. "Synthesis, characterisation and antitumour activities of gallic acid hydrazone and its rare earth complexes." Journal of Chemical Research 2008, no. 11 (2008): 630–32. http://dx.doi.org/10.3184/030823408x371326.

Full text

Abstract:

A new gallic acid hydrazone, 3,4,5-trihydroxybenzoyl salicylaldehyde hydrazone, and its four rare earth complexes, [LnL (OAc)2] • H2O (Ln = La3+, Sm3+, Tb3+, Dy3+), have been synthesised and characterised on the basis of elemental analyses, molar conductivity, IR and 1H NMR spectra. The antitumour activities of the prepared compounds have also been evaluated. The results indicate that Gallic acid hydrazone and its four complexes synthesised possess antitumour activity to some extent, and the four complexes show higher antitumour activity against the human leukaemia cell line HL-60 than the lig

APA, Harvard, Vancouver, ISO, and other styles

31

Sathish, N. K., Raghavendra N.M., and Irfan ali Mohammed. "Anti-tumour Activity of 1, 3- Dimethyl Acridones Against Ehrlich Ascites Carcinoma." International Journal of Drug Design and Discovery 1, no. 4 (2024): 331–35. https://doi.org/10.37285/ijddd.1.4.7.

Full text

Abstract:

We report here in vitro and in vivo antitumour activity study of a series of 1,3-dimethyl-N10 substituted acridone derivatives. All the molecules have been designed on the basis of the presence of specific recognition patterns consisting of electron donor, carbons. Chloro groups with precise spatial separation and structural features (lipophilicity, positive charge at neutral pH and presence of aromatic rings). In vitro and in vivo antitumour effects have been demonstrated against EAC cell-lines. Compounds 2,7,8,9,12,13,14 and 15 exhibited good antitumour activity when compared to Vincristine

APA, Harvard, Vancouver, ISO, and other styles

32

Gielen, M., R. Willem, H. Dalil, D. de Vos, C. M. Kuiper, and G. J. Peters. "Toxicity Profiles In Vivo in Mice and Antitumour Activity in Tumour-Bearing Mice of Di- and Triorganotin Compounds." Metal-Based Drugs 5, no. 2 (1998): 83–90. http://dx.doi.org/10.1155/mbd.1998.83.

Full text

Abstract:

The in vivo toxicity profiles in mice and the antitumour activity in tumour bearing mice were screened for four di-n-butyltin and five triorganotin carboxylates, di-n-butyltin diterebate (5), bis(phenylacetate) (6), bis(deoxycholate) (7), bis(lithocholate) (8), tri-n-butyltin terebate (9), cinnamate (10), and triphenyltin terebate (11).At their maximum tolerated dosis (MTD), no antitumour effect (T/C ~1) was observed for the compounds 5, 7, 9, 10 and 11. The compounds 6 (T/C = 0.51) and 8 (T/C = 0.42) showed clear antitumour activity after single dose administration and might therefore be of i

APA, Harvard, Vancouver, ISO, and other styles

33

Diel, Ingo J. "Antitumour Effects of Bisphosphonates." Drugs 59, no. 3 (2000): 391–99. http://dx.doi.org/10.2165/00003495-200059030-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Bordon, Yvonne. "Antitumour roles for antihistamines." Nature Reviews Immunology 22, no. 1 (2021): 4–5. http://dx.doi.org/10.1038/s41577-021-00670-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Gielen, Marcel. "TIN-BASED ANTITUMOUR DRUGS." Main Group Metal Chemistry 17, no. 1-4 (1994): 1–8. http://dx.doi.org/10.1515/mgmc.1994.17.1-4.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Carmichael, J. "Antitumour Drug-Radiation Interactions." British Journal of Cancer 65, no. 4 (1992): 626. http://dx.doi.org/10.1038/bjc.1992.128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Zitvogel, Laurence, and Guido Kroemer. "Antibodies regulate antitumour immunity." Nature 521, no. 7550 (2015): 35–37. http://dx.doi.org/10.1038/nature14388.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Gielen, Marcel. "Tin-based Antitumour Drugs." Metal-Based Drugs 1, no. 2-3 (1994): 213–19. http://dx.doi.org/10.1155/mbd.1994.213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Gielen, Marcel. "Tin-based antitumour drugs." Coordination Chemistry Reviews 151 (June 1996): 41–51. http://dx.doi.org/10.1016/s0010-8545(96)90193-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Alcaín, Francisco J., and José M. Villalba. "NQO1-directed antitumour quinones." Expert Opinion on Therapeutic Patents 17, no. 6 (2007): 649–65. http://dx.doi.org/10.1517/13543776.17.6.649.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Alderton, Gemma K. "TIM3 suppresses antitumour DCs." Nature Reviews Cancer 12, no. 9 (2012): 584. http://dx.doi.org/10.1038/nrc3349.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Everse, K. E., H. Lin, E. L. Stuyt, J. C. Brady, F. Buddingh, and J. Everse. "Antitumour activity of peroxidases." British Journal of Cancer 51, no. 5 (1985): 743–46. http://dx.doi.org/10.1038/bjc.1985.113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Yadav, J. S. "Synthesis of antitumour agents." Pure and Applied Chemistry 65, no. 6 (1993): 1349–56. http://dx.doi.org/10.1351/pac199365061349.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Alderton, Gemma K. "TIM3 suppresses antitumour DCs." Nature Reviews Immunology 12, no. 9 (2012): 621. http://dx.doi.org/10.1038/nri3288.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Itokawa, Hideji, Hiroshi Morita, Takayoshi Sumitomo, Nobuo Totsuka, and Koichi Takeya. "Antitumour Principles fromAlpinia galanga." Planta Medica 53, no. 01 (1987): 32–33. http://dx.doi.org/10.1055/s-2006-962611.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Gielen, M. "Tin-based antitumour drugs." Coordination Chemistry Reviews 151, no. 1 (1996): 41–51. http://dx.doi.org/10.1016/0010-8545(95)01216-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Alkhuseyn-Kulyaginova, Margarita S., Elizaveta M. Kotieva, Violetta M. Kotieva, Mohamad S. Abou Alou, Margarita A. Dodokhova, and Inga M. Kotieva. "Pathogenetic Aspects of Metronomic Administration of Compounds with an Alleged Antitumour Effect (Review)." Journal of Medical and Biological Research, no. 3 (September 1, 2023): 341–50. http://dx.doi.org/10.37482/2687-1491-z151.

Full text

Abstract:

Chemotherapy is the main treatment method for malignant neoplasms. Classical administration regimens for chemotherapeutic agents are accompanied by strong side effects. Thus, there is a need for a rational mode of administration that can increase the effectiveness of chemotherapy and reduce its side effects. Development of new antitumour drugs must involve testing their pharmacological activity at various administration regimens. At the stage of preclinical studies of new compounds with an alleged antitumour effect, determining an optimal dosage regimen is an urgent task for interdisciplinary

APA, Harvard, Vancouver, ISO, and other styles

48

Manuaba, Ida Bagus Putra. "SYNTHESIS, IDENTIFICATION AND IN VITRO ANTITUMOUR PRESCREENING TEST OF TRIPHENYLTIN BENZOATE TOWARDS A HUMAN CERVICAL CARCINOMA CELL LINE, HeLa." Indonesian Journal of Chemistry 8, no. 3 (2010): 418–22. http://dx.doi.org/10.22146/ijc.21599.

Full text

Abstract:

In this study, triphenyltin benzoate was synthesized first, and followed by antitumor prescreening test of the compound towards a human cervical carcinoma cell line, HeLa. Three reaction steps were employed to obtain the compound needed, i.e. 1) synthesizing of tetraphenyltin compound via insitu phenilmagnesiumbromide Grignard reaction to tin(IV)chloride, 2) synthesizing triphenyltin chloride via redistribution reaction of tetraphenyltin to tin(IV) chloride without any solvent, the reaction completed depends on the temperature, in this case a good results was achieved at temperature 220 °C for

APA, Harvard, Vancouver, ISO, and other styles

49

Di GAETANO, Sonia, Giuseppe D'ALESSIO, and Renata PICCOLI. "Second generation antitumour human RNase: significance of its structural and functional features for the mechanism of antitumour action." Biochemical Journal 358, no. 1 (2001): 241–47. http://dx.doi.org/10.1042/bj3580241.

Full text

Abstract:

A second generation mutant of dimeric human pancreas RNase (HHP2-RNase), was obtained by a single residue mutation (Glu111 → Gly) of the previously described dimeric human pancreas RNase variant (HHP-RNase). HHP2-RNase was found to be a highly specific antitumour agent, with an enhanced cytotoxic activity compared with HHP-RNase. The structural and functional requisites of the antitumour action of HHP2-RNase were investigated and compared with those of other dimeric antitumour RNases. The stability of the dimeric structure, i.e. the resistance of human dimeric RNase variants to reductive cleav

APA, Harvard, Vancouver, ISO, and other styles

50

Chen, Qing, Wang Liu, and Zhongbin Zhoa. "Indoleamine 2,3-Dioxygenase (IDO); Silenced Dendritic Cell Vaccine with Ipilimumab in Treating Metastatic Melanoma Patients: A Case Report." Journal of Clinical and Cellular Immunology 14, no. 3 (2023): 3. https://doi.org/10.35248/2155-9899.23.14.688.

Full text

Abstract:

Immunotherapy has revolutionized the treatment landscape for metastatic melanoma. This case report presents the clinical course of a patient with metastatic melanoma who received combination therapy with ipilimumab, a CTLA-4 checkpoint inhibitor, and an Indoleamine 2,3-Dioxygenase (IDO)-silenced Dendritic Cell (DC) vaccine. The treatment approach aimed to enhance antitumour immunity by blocking immune checkpoints and activating dendritic cells. The patient demonstrated a significant clinical response, indicating the diversification and potentiation of the antitumour effects. This case undersco

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!